

THE CO-OPERATIVE CLINICAL CANCER THERAPY TRUST FUND

England & Wales · Charity number 263424

Details

Other names LYMPHOMA RESEARCH TRUST

Status Registered

Legal form Other

Registered 1971-12-24

Register [View on the Charity Commission register](#)

Contact

Address Trustees Department
5th Floor East
250 Euston Road
London
NW1 2PG

Phone 02034479931

Email carron.lindsay@nhs.net

Website www.lymphoma-research-trust.org.uk

Activities

Objects: THE STUDY AND RELIEF OF THOSE SUFFERING FROM LEUKAEMIA, HODGKINS DISEASE, TUMOURS OF THE LYMPH GLAND OR ANY SIMILAR OR RELATED MALIGNANT DISEASE, BY THE ESTABLISHMENT OF AN INSTITUTION TO SET UP AND MAINTAIN CO-OPERATION BETWEEN CLINICS AND OTHER INSTITUTIONS BY COLLATING RECORDING AND DISSEMINATING THE RESULTS OF CLINICAL THERAPY AND RESEARCH. (FOR DETAILS SEE CLAUSE 2 OF THE DECLARATION OF TRUST).

Activities: The Lymphoma Research Trust supports research into the treatment of lymphoma. It makes grants to medical researchers at the Lymphoma Trials Office who organise clinical trials to see which treatments are most effective.

Classification

- **How:** Makes Grants To Organisations, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies

Geography

- **Area of benefit:** GREAT BRITAIN AND NORTHERN IRELAND
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£104,000	£672,922	-	-
2024-03-31	£120,501	£110,672	-	-
2023-03-31	£129,549	£60,878	-	-
2022-03-31	£142,750	£574,278	-	-
2021-03-31	£208,781	£24,233	-	-

Trustees

Name	Role	Appointed
Paul Smith	Chair	2017-09-08
Dr Christopher McNamara		2022-05-17
Dr Graham Collins		2022-05-17
Michael Ainley		2023-11-14
Penny Clarke		2023-11-14
Professor Jessica Okosun		2023-11-14

THE CO-OPERATIVE CLINICAL CANCER THERAPY TRUST FUND

England & Wales - Charity number 263424

Accounts

Lymphoma Research Trust



Registered as The Co-operative Clinical Cancer Therapy Trust Fund

Charity Registration No. 263424

**Report and Accounts
For the year ended 31 March 2025**

Contents

1. Legal and administrative information
2. Structure, governance and management
3. Objectives and activities
4. Achievements and performance
5. Financial review
6. Plans for future periods
7. Statement of Trustees' responsibilities
8. Independent examiner's report
9. Statement of financial activities
10. Balance sheet
11. Notes to the financial statements

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

1. Legal and administrative information

Name of the charity

The full name of the Lymphoma Research Trust is The Co-operative Clinical Cancer Therapy Trust Fund. The Lymphoma Research Trust is registered with the Charity Commissioners of England and Wales and its registration number is 263424.

Trustees

The trustees who held office during the year were:

Prof. Steve Schey (Chairman) (Retired 19 November 2024)
Mr. Paul Smith (Chair from 20 November 2024)
Prof. Steve Devereux (Retired 20 May 2025)
Dr. Christopher McNamara
Dr. Graham Collins
Prof. Jessica Okosun
Mr. Michael Ainley
Ms. Penny Clarke

Principal office

The principal office of the charity is 5th Floor East, 250 Euston Road, London NW1 2PG.

Advisors

Banker	Coutts & Co 440 The Strand London WC2R 0QS
Investment manager	CCLA Fund Managers Ltd Senator House 85 Queen Victoria Street London EC4V 4ET
Independent examiner	Geoffrey Frost BSc (Hons) FCA Blue Spire Limited Cawley Priory South Pallant Chichester West Sussex PO19 1SY

2. Structure, governance and management

Structure of the charity

The Lymphoma Research Trust was set up as The Co-operative Clinical Cancer Therapy Trust Fund by Deed of Trust dated 2 December 1971.

In 1990 the trustees received permission from the Charity Commission to adopt the informal name of the Lymphoma Research Trust which conveys the main interest of the charity more accurately than its original and official name.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

Recruitment, appointment and training of trustees

Under the terms of its Deed of Trust, the Lymphoma Research Trust must have at least five trustees. New trustees are appointed by the continuing trustees at their meetings, which are held at least twice a year. A majority of the continuing trustees is sufficient to elect a new trustee.

Trustees are kept up to date regularly with changes relating to charity legislation. Conferences organized by legal, financial and investment professionals are available for trustees to attend. The trustees delegate the day-to-day operation of the charity to the administrator.

Risk management policy

The trustees maintain a risk register and actively review the risks which the charity faces on an annual basis.

3. Objectives and activities

The principal objective of the Lymphoma Research Trust is to provide funding for the study and relief of those suffering from Hodgkin disease, tumours of the lymph glands, leukaemia and any similar or related malignant diseases. This objective is fulfilled by the establishment of an institution to set up and maintain co-operation between clinics and other institutions by collating, recording and disseminating the results of clinical therapy and research. In furtherance of these objects, trustees may

- A) Endow, assist or conduct projects of clinical research and therapy concerned with leukaemia, Hodgkin disease, tumours of the lymph glands or any other similar or related malignant disease for the benefit of persons suffering from the same.
- B) Undertake the publication of the results of such projects and any reports incidental thereto.
- C) Endow, furnish and fit out with all necessary furniture and other equipment a clinic to be known as the Co-operative Cancer Therapy Clinic.
- D) To advise, support and assist all organisations, institutions or persons having similar charitable objects.

In formulating and applying these objects, the trustees have regard for the guidance of the Charity Commission on Public Benefit.

The Lymphoma Research Trust does this by making grants to research programmes. In particular, it has supported the work of the Haematology Trials Group, part of the Cancer Trials Centre at University College London, for many years. The Haematology Trials Group is a leading research centre which co-ordinates clinical trials into all types of lymphoma - Hodgkin disease and non-Hodgkin lymphoma.

Grant-making policy

The trustees welcome grant applications from centres of excellence for lymphoma research in the UK. Grant applications are reviewed against the objects of the charity and where relevant or necessary, the trustees will arrange for peer review of applications.

4. Achievements and performance

The Lymphoma Research Trust continues to support the Haematology Trials Group at University College London. During the year the charity approved a new grant of £583,227 to provide funding for the group for three years from January 2025 to December 2027.

This was to fund a clinical trials programme lead (20%), a trials assistant (100%), a project manager (100%) and a statistician (50%). This enables them to improve patient care with the development and optimisation of therapy resulting in a reduction in morbidity and mortality.

The Haematology Trials Group is an active research group with 5 lymphoma trials open to recruitment and 7 at the set-up stage or grant application stage or where patients are being followed up for outcomes to treatment. In addition to this, the group manages a further 28 trials which are in follow up or have now been closed. Further information on the trials can be found on the CR UK and UCL Cancer Trials Centre website at <http://www.ctc.ucl.ac.uk>.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

The continued support from the Lymphoma Research Trust has been fundamental in shaping the Haematology Trials Group and has helped the group succeed in running practice-changing trials.

During the year, the trustees awarded £23,250 to Andrew Mckean of the Royal Marsden NHS Foundation Trust for the project on the phenotyping the immune landscape in breast implant associated anaplastic large cell lymphoma. £39,934 was also awarded to Dr Heather Long of the University of Birmingham for a study into investigating the immune microenvironment of post-transplant lymphoproliferative disease.

5. Financial review

During 2024-25, the Lymphoma Research Trust received many donations from patients, their relatives and friends. Donations amounted to £57,181 (2024: £61,331). Without these donations, the Lymphoma Research Trust's ability to fund essential core research would be severely curtailed and the trustees are very grateful for the support of donors and fundraisers.

The charity received legacies totaling £500 during the year (2024: £10,500). In February 2023 the charity was notified of a potential significant legacy. At this year-end date it was still not possible to quantify the amount the charity may receive, and so no accrual has been made in these accounts for this income.

Investment income was £46,319 (2024: £48,670). This brought income from all sources in the year to a total of £104,000 (2024: £120,501).

Expenditure on generating funds was £22,559 (2024: £18,744). Expenditure on charitable activities was £650,363 (2024: £91,928). Total expenditure for 2024-25 came to £672,922 (2024: £110,672).

Reserves policy

The trustees' policy is to aim that total assets cover at least three years' estimated costs for the management of trials, the cost of one Lymphoma Clinical Fellowship over a three-year period, and the full outstanding costs of specific projects to which the trustees are committed. This is currently estimated to be £808,027.

The level of funds at 31 March 2025 after deducting grant commitments already made was £569,321 (2024: £1,183,837). Trustees recognise that this is below the target level of reserves but this is in the knowledge that there is a period of two years before the core grant will be considered again.

Investment policy

The trustees have wide powers of investment conferred on them by the Deed of Trust.

The Lymphoma Research Trust is invested in the CCLA COIF Charities Investment Fund. The trustees receive regular reports on the performance of their investments and the investment managers meet the trustees once a year.

Given the long-term nature of the work undertaken, the trustees have set an investment strategy for funds, beyond their immediate day to day requirements, which seeks to balance current income with longer term capital appreciation in order to seek to preserve the real value of their funds.

The trustees monitor the cash flow of the charity closely.

6. Plans for future periods

The Lymphoma Research Trust will continue to make grants to support research into the causes and treatments of lymphoma.

Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

7. Statement of Trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Trustees on 18th November 2025 and signed on its behalf by:



Mr P Smith
Trustee

**Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)**

8. Independent Examiner's Report to the Trustees of Lymphoma Research Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Geoffrey Frost BSc(Hons) FCA
Blue Spire Limited
Cawley Priory
South Pallant
Chichester
West Sussex
PO19 1SY

Date 25 November 2025

Lymphoma Research Trust 2024-25

9. Statement of Financial Activities for the year ended 31 March 2025

		Unrestricted Funds	
	Notes	2025	2024
		£	£
Income and endowments from:			
Donations		57,181	61,331
Legacies		500	10,500
Investments	4	46,319	48,670
Total		104,000	120,501
Expenditure:			
Raising funds - investment management costs		7,410	7,976
Raising funds - fundraising costs	3	15,149	10,768
Charitable activities	2	650,363	91,928
Total		672,922	110,672
Net gains/(losses) on investments		(45,594)	126,053
Net income/(expenditure)		(614,516)	135,882
Fund balances brought forward at 31 March 2024		1,183,837	1,047,955
Fund balances carried forward at 31 March 2025		569,321	1,183,837

Lymphoma Research Trust 2024-25

10. Balance sheet as at 31 March 2025

	Notes	Unrestricted Funds	
		2025 £	2024 £
Fixed assets			
Investments	4	1,196,464	1,249,468
Current assets			
Debtors: prepayments and accrued income		9,396	20,262
Cash at bank and in hand		178,288	355,207
Total current assets		<u>187,684</u>	<u>375,469</u>
Current liabilities			
Accruals		(6,800)	(800)
Other creditors		-	(4,503)
Grants payable		(424,337)	(402,597)
Total current liabilities		<u>(431,137)</u>	<u>(407,900)</u>
Net current assets/(liabilities)		<u>(243,453)</u>	<u>(32,431)</u>
Total assets less current liabilities		953,011	1,217,037
Creditors: amounts falling due after one year		(383,690)	(33,200)
Net assets		<u>569,321</u>	<u>1,183,837</u>
Accumulated funds			
Brought forward at 31 March 2024		1,183,837	1,047,955
Surplus/(deficit) for the year		(614,516)	135,882
Total funds		<u>569,321</u>	<u>1,183,837</u>

The notes numbered 1 to 7 form part of these accounts.

Approved by the Board of Trustees on 18th November 2025 and signed on its behalf by:

Mr P Smith
Chairman



.....

Lymphoma Research Trust 2024-25

11. Notes to the Financial Statements

1. Accounting policies

1.1 Accounting convention

The Lymphoma Research Trust is an unincorporated charity registered in England governed by a constitution. The address of the principal office is 5th Floor East, 250 Euston Road, London, NW1 2PG and the charity's operations and principal activities are set out in the trustees' report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011 and UK Generally Accepted Practice.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

1.2 Statement of cash flows

The charity does not include a cash flow statement on the grounds that it is applying FRS 102 Section 1A.

1.3 Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Interest income is recognised using the effective interest method and dividend and rent income is recognised as the charity's right to receive payment is established.

1.4 Recognition of expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under expenditure on charitable activities and includes upkeep of the charity's properties and the cost of administering the activity of the charity.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, and governance costs. They are incurred directly in support of expenditure on the objects of the charity and on raising funds for the charity. Support costs are allocated to expenditure on charitable activities and raising funds on a basis consistent with the use of those funds.

Lymphoma Research Trust 2024-25

11. Notes to the Financial Statements

1. Accounting policies

1.5 Cash & cash equivalents

Cash & cash equivalents includes cash at bank and in hand and cash held within the investment portfolio.

1.6 VAT

The charity is not registered for VAT and is unable to recover VAT incurred. On this basis costs are recorded inclusive of VAT within the SOFA.

1.7 Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value with changes recognised in 'net gains / (losses) on investments' in the SoFA where investments are publicly traded or their fair value can otherwise be measured reliably.

1.8 Debtors receivable and creditors payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.9 Taxation

The charity is considered to pass the tests set out in sections 521 to 536 Income Tax Act 2007 (ITA 2007), as such no income tax is payable on the charity's activities.

1.10 Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Lymphoma Research Trust 2024-25

11. Notes to the Financial Statements (continued)

2. Analysis of charitable expenditure

	2024-25	2023-24
	£	£
Grants to Institutions:		
University College London - Year 1 Core Support 2025	182,556	
University College London - Year 2 Core Support 2026	194,208	-
University College London - Year 3 Core Support 2027	206,463	-
Lymphoma Clinical Trials Fellow	-	71,010
LRT Fellow travel expenses 2025	1,667	-
Andrew McKean - Royal Marsden NHS Fdtn Trust	23,250	
Dr Heather Long grant - University of Birmingham	39,934	
Dr. Aisling Barrett - Oxford Uni Hospitals	-	13,588
Dr Rohan Shotton - Christie & Uni of Manchester	-	18,050
Grant write backs	-	(13,706)
Support costs (note 3)	2,285	2,356
	<u>650,363</u>	<u>91,298</u>

3. Allocation of support costs

Expenditure type:	Basis of apportionment:	Raising funds £	Charitable activities £	Total support costs £
Staff costs	Time spent on activities	3,560	1,440	5,000
Independent examination fees	Proportional to staff costs	470	190	660
Other	Proportional to staff costs	1,620	655	2,275
		<u>5,650</u>	<u>2,285</u>	<u>7,935</u>
Direct costs of raising funds		9,499		
Fund raising costs		<u>15,149</u>		

4. Fixed asset investments

	2025 £	2024 £
Movements in the year		
Market value at 1 April 2024	1,249,468	1,431,391
Add: Acquisitions at cost	-	-
Less: Disposals at carrying value	-	(306,914)
Unrealised (losses)/gains	(53,004)	124,991
Market value at 31 March 2025	<u>1,196,464</u>	<u>1,249,468</u>
Historic cost	<u>1,188,880</u>	<u>1,188,880</u>
Investments comprise:		
CCLA managed funds	<u>1,196,464</u>	<u>1,249,468</u>
Investment income		
	£	£
Dividend income	35,457	39,491
Bank deposit interest	10,862	9,179
	<u>46,319</u>	<u>48,670</u>

5. Independent examiner's remuneration

Governance costs include an amount of £660 payable to the independent examiner (2024: £660) for an independent examination.

6. Trustees' remuneration and related party transactions

The trustees received no remuneration during the year (2024: £0). Travel expenses of £23 were reimbursed to trustees (2024: £53).

There were no related party transactions requiring disclosure in the year under review.

Lymphoma Research Trust 2024-25

11. Notes to the Financial Statements (continued)

7. Financial instruments

The carrying amounts of the charity's financial instruments are as follows:

	2025 £	2024 £
Financial assets		
Measured at fair value through net income/(expenditure):		
Fixed asset investments	<u>1,196,464</u>	<u>1,249,468</u>

The income, expense, net gains and net losses attributable to the charity's financial instruments are summarised as follows:

	2025 £	2024 £
Income and expense		
Financial assets measured at fair value through net income/(expenditure)		
Investment income	35,457	39,491
Investment management fees	<u>(7,410)</u>	<u>(7,976)</u>
	<u>28,047</u>	<u>31,515</u>
	2025 £	2024 £
Net gains and losses (including changes in fair value)		
Financial assets measured at fair value through net income/(expenditure)		
Net gains/(losses) on investments	<u>(45,594)</u>	<u>126,053</u>

Fixed asset investments are held at fair value with valuations obtained by reference to market prices from the appropriate stock exchange, bid prices and last traded prices where applicable.

THE CO-OPERATIVE CLINICAL CANCER THERAPY TRUST FUND

England & Wales - Charity number 263424

Accounts

Lymphoma
Research
Trust



Registered as The Co-operative Clinical Cancer Therapy Trust Fund

Charity Registration No. 263424

**Report and Accounts
For the year ended 31 March 2024**

Contents

1. Legal and administrative information
2. Structure, governance and management
3. Objectives and activities
4. Achievements and performance
5. Financial review
6. Plans for future periods
7. Statement of Trustees' responsibilities
8. Independent examiner's report
9. Statement of financial activities
10. Balance sheet
11. Notes to the financial statements

Lymphoma Research Trust **(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)**

1. Legal and administrative information

Name of the charity

The full name of the Lymphoma Research Trust is The Co-operative Clinical Cancer Therapy Trust Fund. The Lymphoma Research Trust is registered with the Charity Commissioners of England and Wales and its registration number is 263424.

Trustees

The trustees who held office during the year were:

Prof. Steve Schey (Chairman)
Prof. Steve Devereux
Mr. Paul Smith
Dr. Christopher McNamara
Dr. Graham Collins
Prof. Jessica Okosun (Appointed 14th November 2023)
Mr. Michael Ainley (Appointed 14th November 2023)
Ms. Penny Clarke (Appointed 14th November 2023)

Principal office

The principal office of the charity is 5th Floor East, 250 Euston Road, London NW1 2PG.

Advisors

Bankers	Coutts & Co 440 The Strand London WC2R 0QS
Investment managers	CCLA Fund Managers Ltd Senator House 85 Queen Victoria Street London EC4V 4ET
Independent examiner	Geoffrey Frost BSc (Hons) FCA Blue Spire Limited Cawley Priory South Pallant Chichester West Sussex PO19 1SY

2. Structure, governance and management

Structure of the charity

The Lymphoma Research Trust was set up as The Co-operative Clinical Cancer Therapy Trust Fund by Deed of Trust dated 2 December 1971.

In 1990 the trustees received permission from the Charity Commission to adopt the informal name of the Lymphoma Research Trust which conveys the main interest of the charity more accurately than its original and official name.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

Recruitment, appointment and training of trustees

Under the terms of its Deed of Trust, the Lymphoma Research Trust must have at least five trustees. New trustees are appointed by the continuing trustees at their meetings, which are held at least twice a year. A majority of the continuing trustees is sufficient to elect a new trustee.

Trustees are kept up to date regularly with changes relating to charity legislation. Conferences organized by legal, financial and investment professionals are available for trustees to attend. The trustees delegate the day-to-day operation of the charity to the administrator.

Risk management policy

The trustees maintain a risk register and actively review the risks which the charity faces on an annual basis.

3. Objectives and activities

The principal objective of the Lymphoma Research Trust is to provide funding for the study and relief of those suffering from Hodgkin disease, tumours of the lymph glands, leukaemia and similar or related diseases. In formulating and applying these objects, the trustees have regard for the guidance of the Charity Commission on Public Benefit.

The Lymphoma Research Trust does this by making grants to research programmes. In particular, it has supported the work of the Haematology Trials Group, part of the Cancer Trials Centre at University College London, for many years. The Haematology Trials Group is a leading research centre which co-ordinates clinical trials into all types of lymphoma - Hodgkin disease and non-Hodgkin lymphoma.

Grant-making policy

The trustees welcome grant applications from centres of excellence for lymphoma research in the UK. Grant applications are reviewed against the objects of the charity and where relevant or necessary, the trustees will arrange for peer review of applications.

4. Achievements and performance

The Lymphoma Research Trust continues to support the Haematology Trials Group at University College London. The charity continued with the third year of the £502,956 grant to provide funding for the group for three years from January 2022 to December 2024.

This was to fund a tumour group lead (20%), a data manager (100%), a senior trials co-ordinator (100%) and a database developer (50%) which facilitate the maintenance of the trials databases and trials where a long-term assessment of treatment efficacy, and treatment related toxicity is required. This enables them to improve patient care with the development and optimisation of therapy resulting in a reduction in morbidity and mortality.

The charity also continued to provide funding for a Lymphoma Clinical Trials Fellow. In November 2023, £71,010 was granted for the two years from February 2024 to January 2026.

The Haematology Trials Group is an active research group with 4 lymphoma trials open to recruitment and 4 at the set-up stage or grant application stage or where patients are being followed up for outcomes to treatment. In addition to this, the group manages a further 11 trials where results are being written up or presented at conferences. Further information on the trials can be found on the CR UK and UCL Cancer Trials Centre website at <http://www.ctc.ucl.ac.uk>.

The continued support from the Lymphoma Research Trust has been fundamental in shaping the Haematology Trials Group and has helped the group succeed in running practice-changing trials.

During the year, the trustees awarded £13,588 to Dr. Aishling Barrett of the Oxford Cancer and Haematology Centre for the project on the analysis of the biomarker TARC (Thymus and activation-regulated chemokine) in

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

Hodgkin Lymphoma, as part of the AVENUE clinical trial. They also awarded £18,050 to Dr. Rohan Shotton for a project investigating novel biomarkers of anthracycline-related cardiotoxicity.

5. Financial review

During 2023-24, the Lymphoma Research Trust received many donations from patients, their relatives and friends. Donations amounted to £61,331 (2023: £76,989). Without these donations, the Lymphoma Research Trust's ability to fund essential core research would be severely curtailed and the trustees are very grateful for the support of donors and fundraisers.

The charity received legacies totaling £10,500 during the year (2023: £5,000). In February 2023 the charity was notified of a potential legacy. At this year-end date it was still not possible to quantify the amount the charity may receive, and so no accrual has been made in these accounts for this income.

Investment income was £48,670 (2023: £47,560). This brought income from all sources in the year to a total of £120,501 (2023: £129,549).

Expenditure on generating funds was £18,744 (2023: £15,594). Expenditure on charitable activities was £91,928 (2023: £45,284). Total expenditure for 2023-24 came to £110,672 (2023: £60,878).

Reserves policy

The trustees' policy is to ensure that total assets cover at least three years' estimated costs for the management of trials, the cost of one Lymphoma Clinical Fellowship over a three-year period, and the full outstanding costs of specific projects to which the trustees are committed. This is currently estimated to be £810,520.

The level of funds at 31 March 2024 after deducting grant commitments already made was £1,183,837 (2023: £1,047,955).

Investment policy

The trustees have wide powers of investment conferred on them by the Deed of Trust.

The Lymphoma Research Trust is invested in the CCLA COIF Charities Investment Fund. The trustees receive regular reports on the performance of their investments and the investment managers meet the trustees once a year.

Given the long-term nature of the work undertaken, the trustees have set an investment strategy for funds, beyond their immediate day to day requirements, which seeks to balance current income with longer term capital appreciation in order to seek to preserve the real value of their funds.

The trustees monitor the cash flow of the charity closely.

6. Plans for future periods

The Lymphoma Research Trust will continue to make grants to support research into the causes and treatments of lymphoma.

7. Statement of Trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;

Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Trustees on 19th November 2024 and signed on its behalf by:



Mr P Smith
Trustee

**Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)**

8. Independent Examiner's Report to the Trustees of Lymphoma Research Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2024.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Geoffrey Frost BSc(Hons) FCA
Blue Spire Limited
Cawley Priors
South Pallant
Chichester
West Sussex
PO19 1SY

28 November 2024

Date

Lymphoma Research Trust 2023-24

9. Statement of Financial Activities for the year ended 31 March 2024

		Unrestricted Funds	
	Notes	2024	2023
		£	£
Income and endowments from:			
Donations		61,331	76,989
Legacies		10,500	5,000
Investments	4	48,670	47,560
Total		120,501	129,549
Expenditure:			
Raising funds - investment management costs		7,976	8,438
Raising funds - fundraising costs	3	10,768	7,156
Charitable activities	2	91,928	45,284
Total		110,672	60,878
Net gains/(losses) on investments		126,053	(66,674)
Net income/(expenditure)		135,882	1,997
Fund balances brought forward at 31 March 2023		1,047,955	1,045,958
Fund balances carried forward at 31 March 2024		1,183,837	1,047,955

Lymphoma Research Trust 2023-24

10. Balance sheet as at 31 March 2024

	Notes	Unrestricted Funds	
		2024 £	2023 £
Fixed assets			
Investments	4	1,249,468	1,431,391
Current assets			
Debtors: prepayments and accrued income		20,262	11,242
Cash at bank and in hand		355,207	193,122
Total current assets		<u>375,469</u>	<u>204,364</u>
Current liabilities			
Accruals		(800)	(800)
Other creditors		(4,503)	(49,861)
Grants payable		(402,597)	(409,397)
Total current liabilities		<u>(407,900)</u>	<u>(460,058)</u>
Net current assets		<u>(32,431)</u>	<u>(255,694)</u>
Total assets less current liabilities		1,217,037	1,175,697
Creditors: amounts falling due after one year		(33,200)	(127,742)
Net assets		<u>1,183,837</u>	<u>1,047,955</u>
Accumulated funds			
Brought forward at 31 March 2023		1,047,955	1,045,958
Surplus/(deficit) for the year		135,882	1,997
Total funds		<u>1,183,837</u>	<u>1,047,955</u>

The notes numbered 1 to 7 form part of these accounts.

Approved by the Board of Trustees on 19th November 2024 and signed on its behalf by:

Trustee 

Mr P Smith

Lymphoma Research Trust 2023-24

11. Notes to the Financial Statements

1. Accounting policies

1.1 Accounting convention

The Lymphoma Research Trust is an unincorporated charity registered in England governed by a constitution. The address of the principal office is 5th Floor East, 250 Euston Road, London, NW1 2PG and the charity's operations and principal activities are set out in the trustees' report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011 and UK Generally Accepted Practice.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

1.2 Statement of cash flows

The charity does not include a cash flow statement on the grounds that it is applying FRS 102 Section 1A.

1.3 Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Interest income is recognised using the effective interest method and dividend and rent income is recognised as the charity's right to receive payment is established.

1.4 Recognition of expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under expenditure on charitable activities and includes upkeep of the charity's properties and the cost of administering the activity of the charity.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, and governance costs. They are incurred directly in support of expenditure on the objects of the charity and on raising funds for the charity. Support costs are allocated to expenditure on charitable activities and raising funds on a basis consistent with the use of those funds.

Lymphoma Research Trust 2023-24

11. Notes to the Financial Statements

1. Accounting policies

1.5 Cash & cash equivalents

Cash & cash equivalents includes cash at bank and in hand and cash held within the investment portfolio.

1.6 VAT

The charity is not registered for VAT and is unable to recover VAT incurred. On this basis costs are recorded inclusive of VAT within the SOFA.

1.7 Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value with changes recognised in 'net gains / (losses) on investments' in the SoFA where investments are publicly traded or their fair value can otherwise be measured reliably.

1.8 Debtors receivable and creditors payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.9 Taxation

The charity is considered to pass the tests set out in sections 521 to 536 Income Tax Act 2007 (ITA 2007), as such no income tax is payable on the charity's activities.

1.10 Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Lymphoma Research Trust 2023-24

11. Notes to the Financial Statements (continued)

2. Analysis of charitable expenditure

	2023-24	2022-23
	£	£
Grants to Institutions:		
Lymphoma clinical trials fellow	71,010	-
Core Support (Cancer Research UK/UCL Cancer Trials Centre)	-	-
Dr. Daniel Friedman - Kings College London	-	26,930
Dr. Edward Poynton - Barts Cancer Institute	-	45,755
Dr. Aisling Barrett - Oxford Uni Hospitals	13,588	-
Dr Rohan Shotton - Christie & Uni of Manchester	18,050	-
Support costs (note 3)	2,356	2,461
Grant write backs	(13,076)	(29,862)
	<u>91,928</u>	<u>45,284</u>

3. Allocation of support costs

Expenditure type:	Basis of apportionment:	Raising funds £	Charitable activities £	Total support costs £
Staff costs	Time spent on activities	3,560	1,440	5,000
Independent examination fees	Proportional to staff costs	470	190	660
Other	Proportional to staff costs	1,796	726	2,522
		<u>5,826</u>	<u>2,356</u>	<u>8,182</u>
Direct costs of raising funds		4,942		
Fund raising costs		<u>10,768</u>		

4. Fixed asset investments

	2024	2023
	£	£
Movements in the year		
Market value at 1 April 2023	1,431,391	1,506,503
Add: Acquisitions at cost	-	-
Less: Disposals at carrying value	(306,914)	-
Unrealised (losses)/gains	124,991	(75,112)
Market value at 31 March 2024	<u>1,249,468</u>	<u>1,431,391</u>
Historic cost	<u>1,188,880</u>	<u>1,495,795</u>
Investments comprise:		
CCLA managed funds	<u>1,249,468</u>	<u>1,431,391</u>

	2024	2023
	£	£
Investment income		
Dividend income	39,491	43,756
Bank deposit interest	9,179	3,804
	<u>48,670</u>	<u>47,560</u>

5. Independent examiner's remuneration

Governance costs include an amount of £660 payable to the independent examiner (2023: £660) for an independent examination.

6. Trustees' remuneration and related party transactions

The trustees received no remuneration during the year (2023: £0). Travel expenses of £53 were reimbursed to trustees (2023: £26).

There were no related party transactions requiring disclosure in the year under review.

Lymphoma Research Trust 2023-24

11. Notes to the Financial Statements (continued)

7. Financial instruments

The carrying amounts of the charity's financial instruments are as follows:

	2024	2023
	£	£
Financial assets		
Measured at fair value through net income/(expenditure):		
Fixed asset investments	<u>1,249,468</u>	<u>1,431,391</u>

The income, expense, net gains and net losses attributable to the charity's financial instruments are summarised as follows:

	2024	2023
	£	£
Income and expense		
Financial assets measured at fair value through net income/(expenditure)		
Investment income	39,491	43,756
Investment management fees	<u>(7,976)</u>	<u>(8,438)</u>
	<u>31,515</u>	<u>35,318</u>
	2024	2023
	£	£
Net gains and losses (including changes in fair value)		
Financial assets measured at fair value through net income/(expenditure)		
Net gains/(losses) on investments	<u>126,053</u>	<u>(66,674)</u>

Fixed asset investments are held at fair value with valuations obtained by reference to market prices from the appropriate stock exchange, bid prices and last traded prices where applicable.

THE CO-OPERATIVE CLINICAL CANCER THERAPY TRUST FUND

England & Wales - Charity number 263424

Accounts

Lymphoma
Research
Trust



Registered as The Co-operative Clinical Cancer Therapy Trust Fund

Charity Registration No. 263424

Report and Accounts
For the year ended 31 March 2023

Contents

1. Legal and administrative information
2. Structure, governance and management
3. Objectives and activities
4. Achievements and performance
5. Financial review
6. Plans for future periods
7. Statement of Trustees' responsibilities
8. Independent examiner's report
9. Statement of financial activities
10. Balance sheet
11. Notes to the financial statements

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

1. Legal and administrative information

Name of the charity

The full name of the Lymphoma Research Trust is The Co-operative Clinical Cancer Therapy Trust Fund. The Lymphoma Research Trust is registered with the Charity Commissioners of England and Wales and its registration number is 263424.

Trustees

The trustees who held office during the year were:

Prof. Steve Schey (Chairman)
Ms. Margaret Littlejohns (Resigned 8th November 2022)
Prof. Steve Devereux
Mr. Paul Smith
Dr. Christopher McNamara (Appointed 17th May 2022)
Dr. Graham Collins (Appointed 17th May 2022)

Principal office

The principal office of the charity is 5th Floor East, 250 Euston Road, London NW1 2PG.

Advisors

Bankers	Coutts & Co 440 The Strand London WC2R 0QS
Investment managers	CCLA Fund Managers Ltd Senator House 85 Queen Victoria Street London EC4V 4ET
Independent examiner	Geoffrey Frost BSc (Hons) FCA Blue Spire Limited Cawley Priory South Pallant Chichester West Sussex PO19 1SY

2. Structure, governance and management

Structure of the charity

The Lymphoma Research Trust was set up as The Co-operative Clinical Cancer Therapy Trust Fund by Deed of Trust dated 2 December 1971.

In 1990 the trustees received permission from the Charity Commission to adopt the informal name of the Lymphoma Research Trust which conveys the main interest of the charity more accurately than its original and official name.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

Recruitment, appointment and training of trustees

Under the terms of its Deed of Trust, the Lymphoma Research Trust must have at least five trustees. New trustees are appointed by the continuing trustees at their meetings, which are held at least twice a year. A majority of the continuing trustees is sufficient to elect a new trustee.

Trustees are kept up to date regularly with changes relating to charity legislation. Conferences organized by legal, financial and investment professionals are available for trustees to attend. The trustees delegate the day-to-day operation of the charity to the administrator.

Risk management policy

The trustees maintain a risk register and actively review the risks which the charity faces on an annual basis.

3. Objectives and activities

The principal objective of the Lymphoma Research Trust is to provide funding for the study and relief of those suffering from Hodgkin disease, tumours of the lymph glands, leukaemia and similar or related diseases. In formulating and applying these objects, the trustees have regard for the guidance of the Charity Commission on Public Benefit.

The Lymphoma Research Trust does this by making grants to research programmes. In particular, it has supported the work of the Haematology Trials Group, part of the Cancer Trials Centre at University College London, for many years. The Haematology Trials Group is a leading research centre which co-ordinates clinical trials into all types of lymphoma - Hodgkin disease and non-Hodgkin lymphoma.

Grant-making policy

The trustees welcome grant applications from centres of excellence for lymphoma research in the UK. Grant applications are reviewed against the objects of the charity and where relevant or necessary, the trustees will arrange for peer review of applications.

4. Achievements and performance

The Lymphoma Research Trust continues to support the Haematology Trials Group at University College London. The charity continued with the second year of the £502,956 grant to provide funding for the group for three years from January 2022 to December 2024.

This was to fund a tumour group lead (20%), a data manager (100%), a senior trials co-ordinator (100%) and a database developer (50%) which facilitate the maintenance of the trials databases and trials where a long-term assessment of treatment efficacy, and treatment related toxicity is required. This enables them to improve patient care with the development and optimisation of therapy resulting in a reduction in morbidity and mortality.

The charity also continued to provide funding for a Lymphoma Clinical Trials Fellow. In August 2021, £67,915 was granted for the two years from February 2022 to January 2024.

The Haematology Trials Group is an active research group with 4 lymphoma trials open to recruitment and 5 at the set-up stage or grant application stage or where patients are being followed up for outcomes to treatment. In addition to this, the group manages a further 14 trials where results are being written up or presented at conferences. Further information on the trials can be found on the CR UK and UCL Cancer Trials Centre website at <http://www.ctc.ucl.ac.uk>.

The continued support from the Lymphoma Research Trust has been fundamental in shaping the Haematology Trials Group and has helped the group succeed in running practice-changing trials.

During the year, the trustees awarded £26,930 to Dr. Daniel Friedman of King's College London for his project on identifying subfractions of Chronic Lymphocytic Leukaemia (CLL) cells that are primed for activation in the tissue microenvironment. They also awarded £45,755 to Dr. Edward Poynton of Barts Cancer Institute for his project on dissecting the molecular heterogeneity and evolution of central nervous system lymphomas.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

5. Financial review

During 2022-23, the Lymphoma Research Trust received many donations from patients, their relatives and friends. Donations amounted to £76,989 (2022: £96,422). Without these donations, the Lymphoma Research Trust's ability to fund essential core research would be severely curtailed and the trustees are very grateful for the support of donors and fundraisers.

The charity received legacies totaling £5,000 during the year (2022: £3,671). In February 2023 the charity was notified of a potential legacy. At year-end date it was not possible to quantify the amount the charity may receive.

Investment income was £47,560 (2022: £42,637). This brought income from all sources in the year to a total of £129,549 (2022: £142,750).

Expenditure on generating funds was £15,594 (2022: £15,598). Expenditure on charitable activities was £45,284 (2022: £558,680). Total expenditure for 2022-23 came to £60,878 (2022: £574,278).

Reserves policy

The trustees' policy is to ensure that total assets cover at least three years' estimated costs for the management of trials, the cost of one Lymphoma Clinical Fellowship over a three-year period, and the full outstanding costs of specific projects to which the trustees are committed.

The level of funds at 31 March 2023 after deducting grant commitments already made was £1,047,955 (2022: £1,045,958).

Investment policy

The trustees have wide powers of investment conferred on them by the Deed of Trust.

The Lymphoma Research Trust is invested in the CCLA COIF Charities Investment Fund. The trustees receive regular reports on the performance of their investments and the investment managers meet the trustees once a year.

Given the long-term nature of the work undertaken, the trustees have set an investment strategy for funds, beyond their immediate day to day requirements, which seeks to balance current income with longer term capital appreciation in order to seek to preserve the real value of their funds.

The trustees monitor the cash flow of the charity closely.

6. Plans for future periods

The Lymphoma Research Trust will continue to make grants to support research into the causes and treatments of lymphoma.

7. Statement of Trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;

Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Trustees on 14th November 2023 and signed on its behalf by:



Prof S. Schey
Chairman

**Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)**

8. Independent Examiner's Report to the Trustees of Lymphoma Research Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2023.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Geoffrey Frost BSc(Hons) FCA
Blue Spire Limited
Cawley Priory
South Pallant
Chichester
West Sussex
PO19 1SY

20 November 2023

Date

Lymphoma Research Trust 2022-23

9. Statement of Financial Activities for the year ended 31 March 2023

		Unrestricted Funds	
	Notes	2023	2022
		£	£
Income and endowments from:			
Donations		76,989	96,442
Legacies		5,000	3,671
Investments	4	47,560	42,637
Total		129,549	142,750
Expenditure:			
Raising funds - investment management costs		8,438	9,140
Raising funds - fundraising costs	3	7,156	6,458
Charitable activities	2	45,284	558,680
Total		60,878	574,278
Net gains/(losses) on investments		(66,674)	133,250
Net income/(expenditure)		1,997	(298,278)
Fund balances brought forward at 31 March 2022		1,045,958	1,344,236
Fund balances carried forward at 31 March 2023		1,047,955	1,045,958

Lymphoma Research Trust 2022-23

10. Balance sheet as at 31 March 2023

	Notes	Unrestricted Funds	
		2023 £	2022 £
Fixed assets			
Investments	4	1,431,391	1,506,503
Current assets			
Debtors: prepayments and accrued income		11,242	92,585
Cash at bank and in hand		193,122	170,131
Total current assets		<u>204,364</u>	<u>262,716</u>
Current liabilities			
Accruals		(800)	(800)
Other creditors		(49,861)	(29,536)
Grants payable		(409,397)	(343,813)
Total current liabilities		<u>(460,058)</u>	<u>(374,149)</u>
Net current assets		<u>(255,694)</u>	<u>(111,433)</u>
Total assets less current liabilities		1,175,697	1,395,070
Creditors: amounts falling due after one year		(127,742)	(349,112)
Net assets		<u>1,047,955</u>	<u>1,045,958</u>
Accumulated funds			
Brought forward at 31 March 2022		1,045,958	1,344,236
Surplus/(deficit) for the year		1,997	(298,278)
Total funds		<u>1,047,955</u>	<u>1,045,958</u>

The notes numbered 1 to 7 form part of these accounts.

Approved by the Board of Trustees on 14th November 2023

and signed on its behalf by:

Chairman

Lymphoma Research Trust 2022-23

11. Notes to the Financial Statements

1. Accounting policies

1.1 Accounting convention

The Lymphoma Research Trust is an unincorporated charity registered in England governed by a constitution. The address of the principal office is 5th Floor East, 250 Euston Road, London, NW1 2PG and the charity's operations and principal activities are set out in the trustees' report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011 and UK Generally Accepted Practice.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

1.2 Statement of cash flows

The charity does not include a cash flow statement on the grounds that it is applying FRS 102 Section 1A.

1.3 Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Interest income is recognised using the effective interest method and dividend and rent income is recognised as the charity's right to receive payment is established.

1.4 Recognition of expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under expenditure on charitable activities and includes upkeep of the charity's properties and the cost of administering the activity of the charity.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, and governance costs. They are incurred directly in support of expenditure on the objects of the charity and on raising funds for the charity. Support costs are allocated to expenditure on charitable activities and raising funds on a basis consistent with the use of those funds.

Lymphoma Research Trust 2022-23

11. Notes to the Financial Statements

1. Accounting policies

1.5 Cash & cash equivalents

Cash & cash equivalents includes cash at bank and in hand and cash held within the investment portfolio.

1.6 VAT

The charity is not registered for VAT and is unable to recover VAT incurred. On this basis costs are recorded inclusive of VAT within the SOFA.

1.7 Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value with changes recognised in 'net gains / (losses) on investments' in the SoFA where investments are publicly traded or their fair value can otherwise be measured reliably.

1.8 Debtors receivable and creditors payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.9 Taxation

The charity is considered to pass the tests set out in sections 521 to 536 Income Tax Act 2007 (ITA 2007), as such no income tax is payable on the charity's activities.

1.10 Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Lymphoma Research Trust 2022-23

11. Notes to the Financial Statements (continued)

2. Analysis of charitable expenditure

	2022-23	2021-22
	£	£
Grants to Institutions:		
Lymphoma clinical trials fellow	-	67,915
Core Support (Cancer Research UK/UCL Cancer Trials Centre)	-	502,956
Dr. Ugo Offor - Univ. Newcastle	-	30,762
K Linton - Christie NHS Foundation Trust	-	12,697
Dr. Daniel Friedman - Kings College London	26,930	-
Dr. Edward Poynton - Barts Cancer Institute	45,755	-
Support costs (note 3)	2,461	2,281
Grant write backs	(29,862)	(57,931)
	<u>45,284</u>	<u>558,680</u>

3. Allocation of support costs

Expenditure type:	Basis of apportionment:	Raising funds	Charitable activities	Total support costs
		£	£	£
Staff costs	Time spent on activities	3,560	1,440	5,000
Independent examination fees	Proportional to staff costs	470	190	660
Other	Proportional to staff costs	2,053	831	2,884
		<u>6,083</u>	<u>2,461</u>	<u>8,544</u>
Direct costs of raising funds		1,073		
Fund raising costs		<u>7,156</u>		

4. Fixed asset investments

	2023	2022
	£	£
Movements in the year		
Market value at 1 April 2022	1,506,503	1,482,393
Add: Acquisitions at cost	-	1,495,795
Less: Disposals at carrying value	-	(1,482,393)
Unrealised (losses)/gains	(75,112)	10,708
Market value at 31 March 2023	<u>1,431,391</u>	<u>1,506,503</u>
Historic cost	<u>1,495,795</u>	1,495,795
Investments comprise:		
CCLA managed funds	1,431,391	1,506,503
Investment income		
	£	£
Dividend income	43,756	42,584
Bank deposit interest	3,804	53
	<u>47,560</u>	<u>42,637</u>

5. Independent examiner's remuneration

Governance costs include an amount of £660 payable to the independent examiner (2022: £660) for an independent examination.

6. Trustees' remuneration and related party transactions

The trustees received no remuneration during the year (2022: £0). Travel expenses of £26 were reimbursed to trustees (2022: £21).

There were no related party transactions requiring disclosure in the year under review.

Lymphoma Research Trust 2022-23

11. Notes to the Financial Statements (continued)

7. Financial instruments

The carrying amounts of the charity's financial instruments are as follows:

	2023	2022
	£	£

Financial assets

Measured at fair value through net income/(expenditure):

Fixed asset investments	<u>1,431,391</u>	<u>1,506,503</u>
-------------------------	------------------	------------------

The income, expense, net gains and net losses attributable to the charity's financial instruments are summarised as follows:

	2023	2022
	£	£

Income and expense

Financial assets measured at fair value through net income/(expenditure)

Investment income	43,756	42,584
Investment management fees	<u>(8,438)</u>	<u>(9,140)</u>
	<u>35,318</u>	<u>33,444</u>

	2023	2022
	£	£

Net gains and losses (including changes in fair value)

Financial assets measured at fair value through net income/(expenditure)

Net gains/(losses) on investments	<u>(66,674)</u>	<u>133,250</u>
-----------------------------------	-----------------	----------------

Fixed asset investments are held at fair value with valuations obtained by reference to market prices from the appropriate stock exchange, bid prices and last traded prices where applicable.

THE CO-OPERATIVE CLINICAL CANCER THERAPY TRUST FUND

England & Wales - Charity number 263424

Accounts

Lymphoma
Research
Trust

The logo consists of a black L-shaped graphic on the left and a cluster of four overlapping triangles on the right. The triangles are colored in shades of orange and red.

Registered as The Co-operative Clinical Cancer Therapy Trust Fund

Charity Registration No. 263424

Report and Accounts
For the year ended 31 March 2022

Contents

1. Legal and administrative information
2. Structure, governance and management
3. Objectives and activities
4. Achievements and performance
5. Financial review
6. Plans for future periods
7. Statement of Trustees' responsibilities
8. Independent examiner's report
9. Statement of financial activities
10. Balance sheet
11. Notes to the financial statements

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

1. Legal and administrative information

Name of the charity

The full name of the Lymphoma Research Trust is The Co-operative Clinical Cancer Therapy Trust Fund. The Lymphoma Research Trust is registered with the Charity Commissioners of England and Wales and its registration number is 263424.

Trustees

The trustees who held office during the year were:

Prof. Steve Schey (Chairman)
Ms. Margaret Littlejohns
Dr. Catherine Anderson (Resigned 23rd November 2021)
Prof. Steve Devereux
Mr. Paul Smith
Dr. Christopher McNamara (Appointed 17th May 2022)
Dr. Graham Collins (Appointed 17th May 2022)

Principal office

The principal office of the charity is 5th Floor East, 250 Euston Road, London NW1 2PG.

Advisors

Bankers	Coutts & Co 440 The Strand London WC2R 0QS
Investment managers	CCLA Fund Managers Ltd Senator House 85 Queen Victoria Street London EC4V 4ET
Independent examiner	Geoffrey Frost BSc (Hons) FCA Blue Spire Limited Cawley Priory South Pallant Chichester West Sussex PO19 1SY

2. Structure, governance and management

Structure of the charity

The Lymphoma Research Trust was set up as The Co-operative Clinical Cancer Therapy Trust Fund by Deed of Trust dated 2 December 1971.

In 1990 the trustees received permission from the Charity Commission to adopt the informal name of the Lymphoma Research Trust which conveys the main interest of the charity more accurately than its original and official name.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

Recruitment, appointment and training of trustees

Under the terms of its Deed of Trust, the Lymphoma Research Trust must have at least five trustees. New trustees are appointed by the continuing trustees at their meetings, which are held at least twice a year. A majority of the continuing trustees is sufficient to elect a new trustee.

Trustees are kept up to date regularly with changes relating to charity legislation. Conferences organized by legal, financial and investment professionals are available for trustees to attend. The trustees delegate the day-to-day operation of the charity to the administrator.

Risk management policy

The trustees maintain a risk register and actively review the risks which the charity faces on an annual basis.

3. Objectives and activities

The principal objective of the Lymphoma Research Trust is to provide funding for the study and relief of those suffering from Hodgkin disease, tumours of the lymph glands, leukaemia and similar or related diseases. In formulating and applying these objects, the trustees have regard for the guidance of the Charity Commission on Public Benefit.

The Lymphoma Research Trust does this by making grants to research programmes. In particular, it has supported the work of the Haematology Trials Group, part of the Cancer Trials Centre at University College London, for many years. The Haematology Trials Group is a leading research centre which co-ordinates clinical trials into all types of lymphoma - Hodgkin disease and non-Hodgkin lymphoma.

Grant-making policy

The trustees welcome grant applications from centres of excellence for lymphoma research in the UK. Grant applications are reviewed against the objects of the charity and where relevant or necessary, the trustees will arrange for peer review of applications.

4. Achievements and performance

The Lymphoma Research Trust continues to support the Haematology Trials Group at University College London. In August 2021, £502,956 was granted to provide funding for the group for three years from January 2022 to December 2024. This was to fund a tumour group lead (20%), a data manager (100%), a senior trials co-ordinator (100%) and a database developer (50%) which facilitate the maintenance of the trials databases and trials where a long-term assessment of treatment efficacy, and treatment related toxicity is required. This enables them to improve patient care with the development and optimisation of therapy resulting in a reduction in morbidity and mortality. The charity also continued to provide funding for a Lymphoma Clinical Trials Fellow. In August 2021, £67,915 was granted for the two years from February 2022 to January 2024.

The Haematology Trials Group is an active research active group with 4 lymphoma trials open to recruitment and 7 at the set-up stage or grant application stage or where patients are being followed up for outcomes to treatment. In addition to this, the group manages a further 9 trials where results are being written up or presented at conferences. Further information on the trials can be found on the CR UK and UCL Cancer Trials Centre website at <http://www.ctc.ucl.ac.uk>.

The continued support from the Lymphoma Research Trust has been fundamental in shaping the Haematology Trials Group and has helped the group succeed in running practice-changing trials.

During the year, the trustees awarded £30,762 to Dr. Offer of the Wolfson Childhood Cancer Research Centre for his project on investigating Epstein Barr Virus immunity in children at high risk of post-transplant lymphoproliferative diseases. They also awarded £12,697 to Dr. Kim Linton of The Christie NHS Foundation Trust for her project on CSF microRNAs as potential diagnostic and prognostic markers in Primary Central Nervous System Lymphoma.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

5. Financial review

During 2021-22, the Lymphoma Research Trust received many donations from patients, their relatives and friends. Donations amounted to £96,442 (2021: £75,380). Without these donations, the Lymphoma Research Trust's ability to fund essential core research would be severely curtailed and the trustees are very grateful for the support of donors and fundraisers. The charity received legacies totaling £3,671 during the year (2021: £90,000). Investment income was £42,637 (2021: £43,401). This brought income from all sources in the year to a total of £142,750 (2021: £208,781).

Expenditure on generating funds was £15,598 (2021: £22,083). A grant for the core support for 3 years was approved to the Haematology Trials Group, as well as other grants, as discussed above. Expenditure on charitable activities was £558,680 (2021: £2,150). Total expenditure for 2021-22, including the Core Support Grant, came to £574,278 (2021: £24,233).

Reserves policy

The trustees' policy is to ensure that total assets cover at least three years' estimated costs for the management of trials, the cost of one Lymphoma Clinical Fellowship over a three-year period, and the full outstanding costs of specific projects to which the trustees are committed.

The level of funds at 31 March 2022 after deducting grant commitments already made was £1,045,958 compared with £1,344,236 at 31 March 2021.

Investment policy

The trustees have wide powers of investment conferred on them by the Deed of Trust.

The Lymphoma Research Trust is invested in the CCLA COIF Charities Investment Fund. The trustees receive regular reports on the performance of their investments and the investment managers meet the trustees once a year.

Given the long-term nature of the work undertaken, the trustees have set an investment strategy for funds, beyond their immediate day to day requirements, which seeks to balance current income with longer term capital appreciation in order to seek to preserve the real value of their funds.

The trustees monitor the cash flow of the charity closely.

6. Plans for future periods

The Lymphoma Research Trust will continue to make grants to support research into the causes and treatments of lymphoma.

7. Statement of Trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;

Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Trustees on 8th November 2022 and signed on its behalf by:



Prof S. Schey
Chairman

**Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)**

8. Independent Examiner's Report to the Trustees of Lymphoma Research Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Geoffrey Frost BSc(Hons) FCA
Blue Spire Limited
Cawley Priory
South Pallant
Chichester
West Sussex
PO19 1SY

10 November 2022

Date

Lymphoma Research Trust 2021-22

9. Statement of Financial Activities for the year ended 31 March 2022

		Unrestricted Funds	
	Notes	2022 £	2021 £
Income and endowments from:			
Donations		96,442	75,380
Legacies		3,671	90,000
Investments	4	42,637	43,401
Total		142,750	208,781
Expenditure:			
Raising funds - investment management costs		9,140	8,674
Raising funds - fundraising costs		6,458	13,409
Charitable activities	2	558,680	2,150
Total		574,278	24,233
Net gains/(losses) on investments		133,250	262,542
Net income/(expenditure)		(298,278)	447,090
Fund balances brought forward at 31 March 2021		1,344,236	897,146
Fund balances carried forward at 31 March 2022		1,045,958	1,344,236

Lymphoma Research Trust 2021-22

10. Balance sheet as at 31 March 2022

	Notes	Unrestricted Funds	
		2022 £	2021 £
Fixed assets			
Investments	4	1,506,503	1,482,393
Current assets			
Debtors: prepayments and accrued income		92,585	99,214
Cash at bank and in hand		170,131	132,169
Total current assets		<u>262,716</u>	<u>231,383</u>
Current liabilities			
Accruals		(800)	(700)
Other creditors		(29,536)	(39,575)
Grants payable		(343,813)	(240,987)
Total current liabilities		<u>(374,149)</u>	<u>(281,262)</u>
Net current assets		<u>(111,433)</u>	<u>(49,879)</u>
Total assets less current liabilities		1,395,070	1,432,514
Creditors: amounts falling due after one year		(349,112)	(88,278)
Net assets		<u>1,045,958</u>	<u>1,344,236</u>
Accumulated funds			
Brought forward at 31 March 2021		1,344,236	897,146
Surplus/(deficit) for the year		(298,278)	447,090
Total funds		<u>1,045,958</u>	<u>1,344,236</u>


The notes numbered 1 to 7 form part of these accounts.

Approved by the Board of Trustees on

8th November 2022

and signed on its behalf by:

Chairman



Lymphoma Research Trust 2021-22

11. Notes to the Financial Statements

1. Accounting policies

1.1 Accounting convention

The Lymphoma Research Trust is an unincorporated charity registered in England governed by a constitution. The address of the principal office is 5th Floor East, 250 Euston Road, London, NW1 2PG and the charity's operations and principal activities are set out in the trustees' report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011 and UK Generally Accepted Practice.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

1.2 Statement of cash flows

The charity does not include a cash flow statement on the grounds that it is applying FRS 102 Section 1A.

1.3 Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Interest income is recognised using the effective interest method and dividend and rent income is recognised as the charity's right to receive payment is established.

1.4 Recognition of expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under expenditure on charitable activities and includes upkeep of the charity's properties and the cost of administering the activity of the charity.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, and governance costs. They are incurred directly in support of expenditure on the objects of the charity and on raising funds for the charity. Support costs are allocated to expenditure on charitable activities and raising funds on a basis consistent with the use of those funds.

Lymphoma Research Trust 2021-22

11. Notes to the Financial Statements

1. Accounting policies

1.5 Cash & cash equivalents

Cash & cash equivalents includes cash at bank and in hand and cash held within the investment portfolio.

1.6 VAT

The charity is not registered for VAT and is unable to recover VAT incurred. On this basis costs are recorded inclusive of VAT within the SOFA.

1.7 Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value with changes recognised in 'net gains / (losses) on investments' in the SoFA where investments are publicly traded or their fair value can otherwise be measured reliably.

1.8 Debtors receivable and creditors payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.9 Taxation

The charity is considered to pass the tests set out in sections 521 to 536 Income Tax Act 2007 (ITA 2007), as such no income tax is payable on the charity's activities.

1.10 Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Lymphoma Research Trust 2021-22

11. Notes to the Financial Statements (continued)

2. Analysis of charitable expenditure

	2021-22	2020-21
	£	£
Grants to Institutions:		
Lymphoma clinical trials fellow	67,915	-
Core Support (Cancer Research UK/UCL Cancer Trials Centre)	502,956	-
Dr. Ugo Offor - Univ. Newcastle	30,762	-
K Linton - Christie NHS Foundation Trust	12,697	-
Support costs (note 3)	2,281	2,150
Grant write backs	(57,931)	-
	<u>558,680</u>	<u>2,150</u>

3. Allocation of support costs

Expenditure type:	Basis of apportionment:	Raising funds £	Charitable activities £	Total support costs £
Staff costs	Time spent on activities	3,560	1,440	5,000
Independent examination fees	Proportional to staff costs	541	219	760
Other	Proportional to staff costs	1,536	622	2,158
		<u>5,637</u>	<u>2,281</u>	<u>7,918</u>

4. Fixed asset investments

	2022	2021
	£	£
Movements in the year		
Market value at 1 April 2021	1,482,393	1,228,525
Add: Acquisitions at cost	1,495,795	-
Less: Disposals at carrying value	(1,482,393)	-
Unrealised (losses)/gains	10,708	253,868
Market value at 31 March 2022	<u>1,506,503</u>	<u>1,482,393</u>
Historic cost	<u>1,495,795</u>	<u>1,250,000</u>
Investments comprise:		
CCLA managed funds	1,506,503	1,482,393
	2022	2021
	£	£
Investment income		
Dividend income	42,584	43,133
Bank deposit interest	53	268
	<u>42,637</u>	<u>43,401</u>

5. Independent examiner's remuneration

Governance costs include an amount of £660 payable to the independent examiner (2021: £600) for an independent examination.

6. Trustees' remuneration and related party transactions

The trustees received no remuneration during the year (2021: £0). Travel expenses of £21 were reimbursed to trustees (2021: £0).

There were no related party transactions requiring disclosure in the year under review.

Lymphoma Research Trust 2021-22

11. Notes to the Financial Statements (continued)

7. Financial instruments

The carrying amounts of the charity's financial instruments are as follows:

	2022	2021
	£	£
Financial assets		
Measured at fair value through net income/(expenditure):		
Fixed asset investments	<u>1,506,503</u>	<u>1,482,393</u>

The income, expense, net gains and net losses attributable to the charity's financial instruments are summarised as follows:

	2022	2021
	£	£
Income and expense		
Financial assets measured at fair value through net income/(expenditure)		
Investment income	42,584	43,133
Investment management fees	<u>(9,140)</u>	<u>(8,674)</u>
	<u>33,444</u>	<u>34,459</u>
	2022	2021
	£	£
Net gains and losses (including changes in fair value)		
Financial assets measured at fair value through net income/(expenditure)		
Net gains/(losses) on investments	<u>133,250</u>	<u>262,542</u>

Fixed asset investments are held at fair value with valuations obtained by reference to market prices from the appropriate stock exchange, bid prices and last traded prices where applicable.

THE CO-OPERATIVE CLINICAL CANCER THERAPY TRUST FUND

England & Wales - Charity number 263424

Accounts



Registered as The Co-operative Clinical Cancer Therapy Trust Fund

Charity Registration No. 263424

**Report and Accounts
For the year ended 31 March 2021**

Contents

1. Legal and administrative information
2. Structure, governance and management
3. Objectives and activities
4. Achievements and performance
5. Financial review
6. Plans for future periods
7. Statement of Trustees' responsibilities
8. Independent examiner's report
9. Statement of financial activities
10. Balance sheet
11. Notes to the financial statements

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

1. Legal and administrative information

Name of the charity

The full name of the Lymphoma Research Trust is The Co-operative Clinical Cancer Therapy Trust Fund. The Lymphoma Research Trust is registered with the Charity Commissioners of England and Wales and its registration number is 263424.

Trustees

The trustees who held office during the year were:

Prof. Steve Schey (Chairman)
Ms. Margaret Littlejohns
Dr. Catherine Anderson
Prof. Steve Devereux
Mr. Paul Smith

Principal office

The principal office of the charity is 5th Floor East, 250 Euston Road, London NW1 2PG.

Advisors

Bankers	Coutts & Co 440 The Strand London WC2R 0QS
Investment managers	CCLA Fund Managers Ltd Senator House 85 Queen Victoria Street London EC4V 4ET
Independent examiner	Geoffrey Frost BSc (Hons) FCA Blue Spire Limited Cawley Priory South Pallant Chichester West Sussex PO19 1SY

2. Structure, governance and management

Structure of the charity

The Lymphoma Research Trust was set up as The Co-operative Clinical Cancer Therapy Trust Fund by Deed of Trust dated 2 December 1971.

In 1990 the trustees received permission from the Charity Commission to adopt the informal name of the Lymphoma Research Trust which conveys the main interest of the charity more accurately than its original and official name.

Recruitment, appointment and training of trustees

Under the terms of its Deed of Trust, the Lymphoma Research Trust must have at least five trustees. New trustees are appointed by the continuing trustees at their meetings, which are held at least twice a year. A majority of the continuing trustees is sufficient to elect a new trustee.

Trustees are kept up to date regularly with changes relating to charity legislation. Conferences organized by legal, financial and investment professionals are available for trustees to attend. The trustees delegate the day-to-day operation of the charity to the administrator.

Risk management policy

The trustees maintain a risk register and actively review the risks which the charity faces on an annual basis.

Lymphoma Research Trust (Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

3. Objectives and activities

The principal objective of the Lymphoma Research Trust is to provide funding for the study and relief of those suffering from Hodgkin disease, tumours of the lymph glands, leukaemia and similar or related diseases. In formulating and applying these objects, the trustees have regard for the guidance of the Charity Commission on Public Benefit.

The Lymphoma Research Trust does this by making grants to research programmes. In particular, it has supported the work of the Haematology Trials Group, part of the Cancer Trials Centre at University College London, for many years. The Haematology Trials Group is a leading research centre which co-ordinates clinical trials into all types of lymphoma - Hodgkin disease and non-Hodgkin lymphoma.

Grant-making policy

The trustees welcome grant applications from centres of excellence for lymphoma research in the UK. Grant applications are reviewed against the objects of the charity and where relevant or necessary, the trustees will arrange for peer review of applications.

4. Achievements and performance

The Lymphoma Research Trust continues to support the Haematology Trials Group at University College London. The charity continued with the third year of a grant of £449,962 to provide funding for the group for three years from January 2019 to December 2021. This was to fund a tumour group lead (20%), a data manager (100%), a senior trials co-ordinator (100%) and a database developer (50%) which facilitate the maintenance of the trials databases and trials where a long-term assessment of treatment efficacy, and treatment related toxicity is required. This enables them to improve patient care with the development and optimisation of therapy resulting in a reduction in morbidity and mortality. The charity also continued to provide funding for a Lymphoma Clinical Trials Fellow.

The Haematology Trials Group is an active research active group with 7 lymphoma trials open to recruitment and 6 at the set-up stage or grant application stage or where patients are being followed up for outcomes to treatment. In addition to this, the group manages a further 19 trials where results are being written up or presented at conferences. Further information on the trials can be found on the CR UK and UCL Cancer Trials Centre website at <http://www.ctc.ucl.ac.uk>.

The continued support from the Lymphoma Research Trust has been fundamental in shaping the Haematology Trials Group and has helped the group succeed in running practice-changing trials. No additional grants were awarded during the year, but £410,659 was paid out relating to existing grants.

5. Financial review

During 2020-21, the Lymphoma Research Trust received many donations from patients, their relatives and friends. Donations amounted to £75,380 (2020: £61,429). Without these donations, the Lymphoma Research Trust's ability to fund essential core research would be severely curtailed and the trustees are very grateful for the support of donors and fundraisers. The charity received two legacies totaling £90,000 during the year (2020: £88,943). Investment income was £43,401 (2020: £45,373). This brought income from all sources in the year to a total of £208,781 (2020: £195,745).

Expenditure on generating funds was £22,083 (2020: £14,314), largely due to some legal fees associated with one of the legacies. No grants were awarded during the year, and spending on charitable activities was £2,150 (2020: £107,098). Total expenditure for 2020-21 came to £24,233 (2020: £121,412).

Reserves policy

The trustees' policy is to ensure that total assets cover at least three years' estimated costs for the management of trials, the cost of one Lymphoma Clinical Fellowship over a three year period, and the full outstanding costs of specific projects to which the trustees are committed.

The level of funds at 31 March 2021 after deducting grant commitments already made was £1,344,236 compared with £897,146 at 31 March 2020.

Lymphoma Research Trust **(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)**

Investment policy

The trustees have wide powers of investment conferred on them by the Deed of Trust.

The Lymphoma Research Trust is invested in the CCLA COIF Charities Investment Fund. The trustees receive regular reports on the performance of their investments and the investment managers meet the trustees once a year.

Given the long term nature of the work undertaken, the trustees have set an investment strategy for funds, beyond their immediate day to day requirements, which seeks to balance current income with longer term capital appreciation in order to seek to preserve the real value of their funds.

The trustees monitor the cash flow of the charity closely.

6. Plans for future periods

The Lymphoma Research Trust will continue to make grants to support research into the causes and treatments of lymphoma.

7. Statement of Trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Trustees on 23 Nov 2021 and signed on its behalf by:



Prof S. Schey
Chairman

Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)

8. Independent Examiner's Report to the Trustees of Lymphoma Research Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2021.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Geoffrey Frost BSc(Hons) FCA
Blue Spire Limited
Cawley Priory
South Pallant
Chichester
West Sussex
PO19 1SY

07 January 2022

Date

Lymphoma Research Trust 2020-21

9. Statement of Financial Activities for the year ended 31 March 2021

		Unrestricted Funds	
	Notes	2021 £	2020 £
Income and endowments from:			
Donations		75,380	61,429
Legacies		90,000	88,943
Investments	4	43,401	45,373
Total		208,781	195,745
Expenditure:			
Raising funds - investment management costs		8,674	8,027
Raising funds - fundraising costs		13,409	6,287
Charitable activities	2	2,150	107,098
Total		24,233	121,412
Net gains/(losses) on investments		262,542	(32,145)
Net income/(expenditure)		447,090	42,188
Fund balances brought forward at 31 March 2020		897,146	854,958
Fund balances carried forward at 31 March 2021		1,344,236	897,146

Lymphoma Research Trust 2020-21

10. Balance sheet as at 31 March 2021

		Unrestricted Funds	
	Notes	2021 £	2020 £
Fixed assets			
Investments	4	1,482,393	1,228,525
Current assets			
Debtors: prepayments and accrued income		99,214	11,324
Cash at bank and in hand		132,169	404,848
Total current assets		231,383	416,172
Current liabilities			
Accruals		(700)	(700)
Other creditors		(39,575)	(6,927)
Grants payable		(240,987)	(581,668)
Total current liabilities		(281,262)	(589,295)
Net current assets		(49,879)	(173,123)
Total assets less current liabilities		1,432,514	1,055,402
Creditors: amounts falling due after one year		(88,278)	(158,256)
Net assets		1,344,236	897,146
Accumulated funds			
Brought forward at 31 March 2020		897,146	854,958
Surplus for the year		447,090	42,188
Total funds		1,344,236	897,146

The notes numbered 1 to 7 form part of these accounts.

Approved by the Board of Trustees on 23 November 2021

and signed on its behalf by:

Chairman



Lymphoma Research Trust 2020-21

11. Notes to the Financial Statements

1. Accounting policies

1.1 Accounting convention

The Lymphoma Research Trust is an unincorporated charity registered in England governed by a constitution. The address of the principal office is 5th Floor East, 250 Euston Road, London, NW1 2PG and the charity's operations and principal activities are set out in the trustees' report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011 and UK Generally Accepted Practice.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

1.2 Statement of cash flows

The charity does not include a cash flow statement on the grounds that it is applying FRS 102 Section 1A.

1.3 Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Interest income is recognised using the effective interest method and dividend and rent income is recognised as the charity's right to receive payment is established.

1.4 Recognition of expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under expenditure on charitable activities and includes upkeep of the charity's properties and the cost of administering the activity of the charity.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, and governance costs. They are incurred directly in support of expenditure on the objects of the charity and on raising funds for the charity. Support costs are allocated to expenditure on charitable activities and raising funds on a basis consistent with the use of those funds.

Lymphoma Research Trust 2020-21

11. Notes to the Financial Statements

1. Accounting policies

1.5 Cash & cash equivalents

Cash & cash equivalents includes cash at bank and in hand and cash held within the investment portfolio.

1.6 VAT

The charity is not registered for VAT and is unable to recover VAT incurred. On this basis costs are recorded inclusive of VAT within the SOFA.

1.7 Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value with changes recognised in 'net gains / (losses) on investments' in the SoFA where investments are publicly traded or their fair value can otherwise be measured reliably.

1.8 Debtors receivable and creditors payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.9 Taxation

The charity is considered to pass the tests set out in sections 521 to 536 Income Tax Act 2007 (ITA 2007), as such no income tax is payable on the charity's activities.

1.10 Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Lymphoma Research Trust 2020-21

11. Notes to the Financial Statements (continued)

2. Analysis of charitable expenditure

	2020-21	2019-20
	£	£
Grants to Institutions:		
Lymphoma clinical trials fellow	-	82,946
Dr. Christopher Carey	-	21,981
Support costs (note 3)	2,150	2,171
	<u>2,150</u>	<u>107,098</u>

3. Allocation of support costs

Expenditure type:		Basis of apportionment:	Raising funds	Charitable activities	Total support costs
			£	£	£
Staff costs		Time spent on activities	3,560	1,440	5,000
Independent examination fees		Proportional to staff costs	427	173	600
Other		Proportional to staff costs	1,325	536	1,862
			<u>5,312</u>	<u>2,150</u>	<u>7,462</u>

4. Fixed asset investments

	2021	2020
	£	£
Movements in the year		
Market value at 1 April 2020	1,228,525	1,268,697
Add: Acquisitions at cost	-	-
Less: Disposals at carrying value	-	-
Unrealised (losses)/gains	253,868	(40,172)
Market value at 31 March 2021	<u>1,482,393</u>	<u>1,228,525</u>
Historic cost	<u>1,250,000</u>	<u>1,250,000</u>
Investments comprise:		
CCLA managed funds	<u>1,482,393</u>	<u>1,228,525</u>

	2021	2020
	£	£
Investment income		
Dividend income	43,133	43,454
Bank deposit interest	268	1,919
	<u>43,401</u>	<u>45,373</u>

5. Independent examiner's remuneration

Governance costs include an amount of £600 payable to the independent examiner (2020: £600) for an independent examination.

6. Trustees' remuneration and related party transactions

The trustees received no remuneration during the year (2020: nil). No travel expenses were reimbursed to trustees (2020: £28).

There were no related party transactions requiring disclosure in the year under review.

Lymphoma Research Trust 2021-20

11. Notes to the Financial Statements (continued)

7. Financial instruments

The carrying amounts of the charity's financial instruments are as follows:

	2021	2020
	£	£
Financial assets		
Measured at fair value through net income/(expenditure):		
Fixed asset investments	<u>1,482,393</u>	<u>1,228,525</u>

The income, expense, net gains and net losses attributable to the charity's financial instruments are summarised as follows:

	2021	2020
	£	£
Income and expense		
Financial assets measured at fair value through net income/(expenditure)		
Investment income	43,133	43,454
Investment management fees	<u>(8,674)</u>	<u>(8,027)</u>
	<u>34,458</u>	<u>35,427</u>

	2021	2020
	£	£
Net gains and losses (including changes in fair value)		
Financial assets measured at fair value through net income/(expenditure)		
Net gains/(losses) on investments	<u>262,542</u>	<u>(32,145)</u>

Fixed asset investments are held at fair value with valuations obtained by reference to market prices from the appropriate stock exchange, bid prices and last traded prices where applicable.